Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.
Advanced Cancer
DRUG: CM082 Tablet
Maximum Tolerated Dose, To determine the Maximum Tolerated Dose in Chinese patients with advanced solid tumors., 12 months
Preliminary biological activity, clinical tumor response by computed tomography (CT) after treatment with CM082 tablets given as a single agent., 24 months|Area Under Curve, 2 months|Half-life time, 2 months|Cmax, Peak concentration, 2 months|Tmax, Time to Cmax, 2 months
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors. After the maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion cohort of \~20 advanced renal cell carcinoma patients will be enrolled to further characterize the safety and tumor response by CT.